STAB logo

Statera Biopharma (STAB) Company Overview

Profile

Full Name:

Statera Biopharma, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 28, 2021

Indexes:

Not included

Description:

Statera Biopharma focuses on developing innovative therapies for autoimmune and inflammatory diseases. The company aims to improve patient outcomes by creating treatments that restore balance in the immune system. Their research combines advanced science with a commitment to addressing unmet medical needs.

Events Calendar

Earnings

Next earnings date:

Feb 7, 2025

Recent quarterly earnings:

Nov 15, 2021

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 28, 2015

Analyst ratings

Recent major analysts updates

No data about analysts updates

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

BNP Paribas Primary New Issues: POST STAB Notice - OVH Groupe SA
BNP Paribas Primary New Issues: POST STAB Notice - OVH Groupe SA
BNP Paribas Primary New Issues: POST STAB Notice - OVH Groupe SA
STAB
globenewswire.comJanuary 31, 2025

29/1/2025 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [OVH Groupe SA] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 29/1/2025] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: POST-STAB: No Stab Notice
BNP Paribas Primary New Issues: POST-STAB: No Stab Notice
BNP Paribas Primary New Issues: POST-STAB: No Stab Notice
STAB
globenewswire.comJanuary 27, 2025

[27/01/2025] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [ELIOR GROUP S.A.

IRCA BNP Paribas Primary New Issues: NO STAB Notice
IRCA BNP Paribas Primary New Issues: NO STAB Notice
IRCA BNP Paribas Primary New Issues: NO STAB Notice
STAB
globenewswire.comDecember 4, 2024

04/12/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. IRCA S.P.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 27/11/24  BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice B&M
BNP Paribas Primary New Issues: STAB Notice B&M
BNP Paribas Primary New Issues: STAB Notice B&M
STAB
globenewswire.comNovember 22, 2024

22 November, 2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. B&M (BME LN) Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 19 th November 2024  BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: NO STAB Notice: TUI CRUISES
BNP Paribas Primary New Issues: NO STAB Notice: TUI CRUISES
BNP Paribas Primary New Issues: NO STAB Notice: TUI CRUISES
STAB
globenewswire.comNovember 22, 2024

[22/11/2024] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. TUI CRUISES GMBH Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 19/11/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Correction: BNP Paribas Primary New Issues: Post-Stab - No STAB Notice - Webuild Spa
Correction: BNP Paribas Primary New Issues: Post-Stab - No STAB Notice - Webuild Spa
Correction: BNP Paribas Primary New Issues: Post-Stab - No STAB Notice - Webuild Spa
STAB
globenewswire.comOctober 23, 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice
BNP Paribas Primary New Issues: STAB Notice
BNP Paribas Primary New Issues: STAB Notice
STAB
globenewswire.comOctober 23, 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB Notice - LION/POLARIS (PICARD)
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - LION/POLARIS (PICARD)
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - LION/POLARIS (PICARD)
STAB
globenewswire.comOctober 23, 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. LION/POLARIS LUX 4 S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB Notice - ACCORINVEST GROUP S.A
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - ACCORINVEST GROUP S.A
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - ACCORINVEST GROUP S.A
STAB
globenewswire.comOctober 23, 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ACCORINVEST GROUP S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB - ILIAD S.A
BNP Paribas Primary New Issues: Post Stab - No STAB - ILIAD S.A
BNP Paribas Primary New Issues: Post Stab - No STAB - ILIAD S.A
STAB
globenewswire.comOctober 23, 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ILIAD S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Statera Biopharma?
  • Does Statera Biopharma pay dividends?
  • What sector is Statera Biopharma in?
  • What industry is Statera Biopharma in?
  • What country is Statera Biopharma based in?
  • When did Statera Biopharma go public?
  • Is Statera Biopharma in the S&P 500?
  • Is Statera Biopharma in the NASDAQ 100?
  • Is Statera Biopharma in the Dow Jones?
  • When was Statera Biopharma's last earnings report?
  • When does Statera Biopharma report earnings?

What is the ticker symbol for Statera Biopharma?

The ticker symbol for Statera Biopharma is NASDAQ:STAB

Does Statera Biopharma pay dividends?

No, Statera Biopharma does not pay dividends

What sector is Statera Biopharma in?

Statera Biopharma is in the Healthcare sector

What industry is Statera Biopharma in?

Statera Biopharma is in the Biotechnology industry

What country is Statera Biopharma based in?

Statera Biopharma is headquartered in United States

When did Statera Biopharma go public?

Statera Biopharma's initial public offering (IPO) was on July 28, 2021

Is Statera Biopharma in the S&P 500?

No, Statera Biopharma is not included in the S&P 500 index

Is Statera Biopharma in the NASDAQ 100?

No, Statera Biopharma is not included in the NASDAQ 100 index

Is Statera Biopharma in the Dow Jones?

No, Statera Biopharma is not included in the Dow Jones index

When was Statera Biopharma's last earnings report?

Statera Biopharma's most recent earnings report was on Nov 15, 2021

When does Statera Biopharma report earnings?

The next expected earnings date for Statera Biopharma is Feb 7, 2025